Intrexon unit pushes back against claims its GM mosquitoes are making disease-friendly mutants
When the hysteria of Zika transmission sprang into the American zeitgeist a few years ago, UK-based Oxitec was already field-testing its male Aedes aegypti mosquito, crafted to possess a gene engineered to obliterate its progeny long before maturation.
But when a group of independent scientists evaluated the impact of the release of these genetically-modified mosquitoes in a trial conducted by Oxitec in Brazil between 2013 and 2015, they found that some of the offspring had managed to survive — prompting them to speculate what impact the survivors could have on disease transmission and/or insecticide resistance.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,400+ biopharma pros reading Endpoints daily — and it's free.